Nivolumab – November 2023

• Brand names:
  • Opdivo®
• Pharmaceutical Company:
  • Bristol-Myers Squibb Australia Pty Ltd
• Condition/Indication: Muscle invasive urothelial carcinoma (MIUC)
• Meeting Date: November 2023
• Public Summary Document (PSD) November 2023 March 2024 PBAC Meetings - (PDF 1.4MB)
• Public Summary Document (PSD) November 2023 March 2024 PBAC Meetings - (Word 604kB)

Related Public Summary Documents

• Nivolumab – March 2024